{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:25:21Z","timestamp":1790832321599,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"BC Cancer Foundation"},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1061"],"award-info":[{"award-number":["1061"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.blre.2017.12.001","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T18:21:18Z","timestamp":1513794078000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies"],"prefix":"10.1016","volume":"32","author":[{"given":"David D.W.","family":"Twa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mottok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2017.12.001_bb0005","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"6","key":"10.1016\/j.blre.2017.12.001_bb0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(02)00776-3","article-title":"An oncological view on the blood-testis barrier","volume":"3","author":"Bart","year":"2002","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2017.12.001_bb0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0020","first-page":"75","article-title":"Primary testicular lymphoma and AIDS","volume":"40","author":"Verma","year":"2010","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2017.12.001_bb0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.3800691","article-title":"Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases","volume":"19","author":"Al-Abbadi","year":"2006","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.blre.2017.12.001_bb0035","first-page":"1261","article-title":"Primary testicular lymphoma: a strictly homogeneous hematological disease?","volume":"23","author":"Kemmerling","year":"2010","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.blre.2017.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3109\/10428194.2013.834055","article-title":"Gene translocations in testicular lymphomas","volume":"55","author":"Bernasconi","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2017.12.001_bb0045","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/02841860410002851","article-title":"Testicular lymphoma\u2014a retrospective, population-based, clinical and immunohistochemical study","volume":"43","author":"Hasselblom","year":"2004","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.blre.2017.12.001_bb0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.prp.2010.04.005","article-title":"Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype","volume":"206","author":"Li","year":"2010","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/path.2033","article-title":"Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics","volume":"210","author":"Booman","year":"2006","journal-title":"J PatholJ Pathol"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"28","author":"Kraan","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/bjc.1995.15","article-title":"Lymphomas with testicular localisation show a consistent BCL-2 expression without a translocation (14;18): a molecular and immunohistochemical study","volume":"71","author":"Lambrechts","year":"1995","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hon.2090","article-title":"Phenotype profiling of primary testicular diffuse large B-cell lymphomas","volume":"32","author":"Menter","year":"2014","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.blre.2017.12.001_bb0075","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/pin.12336","article-title":"High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses","volume":"65","author":"Oishi","year":"2015","journal-title":"Pathol Int"},{"issue":"31","key":"10.1016\/j.blre.2017.12.001_bb0080","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","article-title":"Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab","volume":"27","author":"Gundrum","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.blre.2017.12.001_bb0085","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era","volume":"176","author":"Kridel","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2017.12.001_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.blre.2017.12.001_bb0100","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/leu.2015.237","article-title":"Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the international PTL consortium","volume":"30","author":"Deng","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2017.12.001_bb0120","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2017.12.001_bb0130","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/path.4522","article-title":"Recurrent genomic rearrangements in primary testicular lymphoma","volume":"236","author":"Twa","year":"2015","journal-title":"J. Pathol."},{"issue":"14","key":"10.1016\/j.blre.2017.12.001_bb0140","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.ejca.2004.05.010","article-title":"The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours","volume":"40","author":"Bart","year":"2004","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.blre.2017.12.001_bb0145","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-05-2617","article-title":"Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma","volume":"12","author":"Booman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2017.12.001_bb0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1479-5876-11-123","article-title":"Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer\/testis antigens in diffuse large B-cell testicular lymphoma","volume":"11","author":"Hudolin","year":"2013","journal-title":"J Transl Med"},{"issue":"11","key":"10.1016\/j.blre.2017.12.001_bb0155","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0046-8177(98)90250-7","article-title":"Molecular pathological analysis of testicular diffuse large cell lymphomas","volume":"29","author":"Hyland","year":"1998","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.blre.2017.12.001_bb0160","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"96","author":"Riemersma","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0165","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.14054","article-title":"Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma","volume":"174","author":"Koresawa","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2017.12.001_bb0170","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/PAS.0000000000000648","article-title":"Expression of OCT4 and SALL4 in diffuse large B-cell lymphoma: an analysis of 145 consecutive cases and testicular lymphomas","volume":"40","author":"Williams","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2017.12.001_bb0175","first-page":"1","article-title":"Primary testicular diffuse large B-cell lymphoma: morphological and immunophenotypical study with characterization of the T-cell component of the tumor microenvironment","author":"Magnoli","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2015.299","article-title":"FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas","volume":"30","author":"Brown","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2017.12.001_bb0185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/leu.2010.302","article-title":"The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma","volume":"25","author":"Ruminy","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2017.12.001_bb0190","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","article-title":"High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy","volume":"88","author":"Li","year":"2012","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2017.12.001_bb0195","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.leu.2403488","article-title":"AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity","volume":"18","author":"Lossos","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2017.12.001_bb0200","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood-2004-04-1558","article-title":"Expression of the AID protein in normal and neoplastic B cells","volume":"104","author":"Pasqualucci","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.12.001_bb0205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.blre.2017.12.001_bb0210","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2017.12.001_bb0215","first-page":"53","article-title":"Emerging targets in human lymphoma: targeting the MYD88 mutation","volume":"3","author":"Wang","year":"2013","journal-title":"Blood and Lymphatic Cancer: Targets and Therapy"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2012.170","article-title":"T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis","volume":"26","author":"Kuper-Hommel","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0225","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3892\/mmr.2014.2662","article-title":"Effect of microRNA-21 on multidrug resistance reversal in A549\/DDP human lung cancer cells","volume":"11","author":"Dong","year":"2015","journal-title":"Mol Med Rep"},{"issue":"17","key":"10.1016\/j.blre.2017.12.001_bb0230","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.18632\/oncotarget.3729","article-title":"MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K\/AKT pathway in diffuse large B-cell lymphoma","volume":"6","author":"Go","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.blre.2017.12.001_bb0235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/modpathol.2009.10","article-title":"Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma","volume":"22","author":"Robertus","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2017.12.001_bb0240","first-page":"1","article-title":"Structural genomic alterations in primary mediastinal large B-cell lymphoma","author":"Twa","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2017.12.001_bb0245","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.humpath.2008.06.032","article-title":"BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome","volume":"40","author":"Tibiletti","year":"2009","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0250","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/path.1783","article-title":"High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis","volume":"206","author":"Riemersma","year":"2005","journal-title":"J PatholJ Pathol"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2017.12.001_bb0255","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1080\/10428190310001623775","article-title":"Gene expression profiling of diffuse large B-cell lymphoma","volume":"44","author":"Rosenwald","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.10824","article-title":"Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system","volume":"103","author":"Jordanova","year":"2003","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.blre.2017.12.001_bb0265","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression","volume":"13","author":"Mottok","year":"2015","journal-title":"Cell Rep."},{"issue":"7338","key":"10.1016\/j.blre.2017.12.001_bb0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.blre.2017.12.001_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0010072","article-title":"Folding free energies of 5'-UTRs impact post-transcriptional regulation on a genomic scale in yeast","volume":"1","author":"Ringner","year":"2005","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"10.1016\/j.blre.2017.12.001_bb0280","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.humimm.2014.01.006","article-title":"MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer","volume":"75","author":"Zhu","year":"2014","journal-title":"Hum Immunol"},{"issue":"7607","key":"10.1016\/j.blre.2017.12.001_bb0285","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2017.12.001_bb0290","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1095\/biolreprod31.4.785","article-title":"Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline","volume":"31","author":"Johnson","year":"1984","journal-title":"Biol Reprod"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0295","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/pr400769z","article-title":"Secretome analysis of testicular peritubular cells: a window into the human testicular microenvironment and the spermatogonial stem cell niche in man","volume":"13","author":"Flenkenthaler","year":"2014","journal-title":"J Proteome Res"},{"issue":"1","key":"10.1016\/j.blre.2017.12.001_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0378(02)00060-8","article-title":"Cytokines and the immune-testicular axis","volume":"58","author":"Hedger","year":"2003","journal-title":"J Reprod Immunol"},{"issue":"8","key":"10.1016\/j.blre.2017.12.001_bb0305","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.blre.2017.12.001_bb0310","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.blre.2017.12.001_bb0315","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.12.001_bb0320","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0325","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.blre.2017.12.001_bb0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2017.12.001_bb0335","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2017.12.001_bb0340","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T16:24:35Z","timestamp":1603556675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X17300681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0268960X17300681"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2017.12.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}